Syncom Formulations (India) Limited (NSE:SYNCOMF)
19.09
-0.07 (-0.37%)
Jun 23, 2025, 1:28 PM IST
NSE:SYNCOMF Revenue
In the fiscal year ending March 31, 2025, Syncom Formulations (India) had annual revenue of 4.65B INR with 76.55% growth. Syncom Formulations (India) had revenue of 1.49B in the quarter ending March 31, 2025, with 99.64% growth.
Revenue
4.65B
Revenue Growth
+76.55%
P/S Ratio
3.88
Revenue / Employee
4.66M
Employees
998
Market Cap
18.02B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 4.65B | 2.02B | 76.55% |
Mar 31, 2024 | 2.63B | 391.33M | 17.45% |
Mar 31, 2023 | 2.24B | 45.91M | 2.09% |
Mar 31, 2022 | 2.20B | -251.42M | -10.27% |
Mar 31, 2021 | 2.45B | 392.94M | 19.12% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 525.78B |
Divi's Laboratories | 93.60B |
Cipla | 272.67B |
Apollo Hospitals Enterprise | 217.94B |
Zydus Lifesciences | 232.42B |
Mankind Pharma | 122.07B |
Aurobindo Pharma | 317.24B |
Alkem Laboratories | 129.65B |